A recent NACCHO report reveals alarming staff shortages in local health departments, raising concerns about the public health safety net. As many as 19% report job losses, with funding cuts looming. Discover the implications for your community.
A new Covid variant, NB.1.8.1, raises alarms for its potential to spread rapidly and evade antibodies. Meanwhile, the FDA approves a long-lasting HIV injection, and concerns about public safety arise with ICE's rule changes.
The FDA has updated warnings about potential cardiac risks associated with Pfizer and Moderna COVID-19 vaccines, especially for young men. Learn what the new labels say and what it means for vaccine safety.
A new monoclonal antibody called clesrovimab has been recommended for infants to prevent RSV, stirring debate among health experts and advocates. The FDA approved the treatment just weeks ago.
In a significant move for food safety, Nestlé USA and Conagra Brands announce plans to eliminate synthetic colors from their products. This decision follows growing health concerns and political pressure, aiming to improve nutritional quality in American diets.
The FDA has approved lenacapavir, a groundbreaking antiviral drug for HIV prevention developed by biochemist Wesley Sundquist. Learn how this drug could change the future of HIV treatment and prevention.
A groundbreaking HIV prevention shot, Yeztugo, has been approved by the FDA, offering hope for at-risk individuals with its twice-yearly injections. However, concerns about cost and accessibility remain.
From the shocking endorsement of bleach solutions by RFK Jr. to the discovery of how axolotls regenerate limbs, this article dives into the latest news that is stirring both scientific curiosity and controversy. Discover the implications of these findings!
The FDA has approved Gilead's Yeztugo, a twice-yearly injection that could revolutionize HIV prevention, boasting a 99.9% effectiveness. While hailed as a breakthrough, concerns over pricing remain, with activists urging for affordability.
The U.S. has approved a groundbreaking twice-a-year shot, lenacapvir, for HIV prevention, potentially transforming care. Experts suggest this could significantly reduce new infections.
